Common use of IRO Engagement Clause in Contracts

IRO Engagement. GSK shall engage an IRO (or IRO(s)) that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph D. Within 30 days after OIG receives the information identified in Section V.A.11 of the CIA or any additional information submitted by GSK in response to a request by OIG, whichever is later, OIG will notify GSK if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, GSK may continue to engage the IRO. If GSK engages a new IRO during the term of the CIA, this IRO shall also meet the requirements of this Appendix. If a new IRO is engaged, GSK shall submit the information identified in Section V.A.11 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by GSK at the request of OIG, whichever is later, OIG will notify GSK if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, GSK may continue to engage the IRO.

IRO Engagement. GSK WellCare shall engage an IRO (or IRO(s)) that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review Reviews in a professionally independent and objective fashion, as set forth in Paragraph D. Within 30 days after OIG receives the information identified in Section V.A.11 V.A.8 and Section V.A.9 of the CIA or any additional information submitted by GSK in response to a request by OIG, whichever is laterCIA, OIG will notify GSK WellCare if the IRO is IRO(s) is/are unacceptable. Absent notification from OIG that the IRO is IRO(s) is/are unacceptable, GSK WellCare may continue to engage the IRO. If GSK WellCare engages a new IRO during the term of the CIA, this IRO shall also meet the requirements of this Appendix. If a new IRO is engaged, GSK WellCare shall submit the information identified in Section V.A.11 V.A.8 and Section V.A.9 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by GSK at the request of OIG, whichever is laterinformation, OIG will notify GSK WellCare if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, GSK WellCare may continue to engage the IRO.

IRO Engagement. GSK Amgen shall engage an IRO (or IRO(s)) that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph D. Within 30 days after OIG receives the information identified in Section V.A.11 V.A.10 of the CIA or any additional information submitted by GSK Amgen in response to a request by OIG, whichever is later, OIG will notify GSK Amgen if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, GSK Amgen may continue to engage the IRO. If GSK Amgen engages a new IRO during the term of the CIA, this IRO shall also meet the requirements of this Appendix. If a new IRO is engaged, GSK Amgen shall submit the information identified in Section V.A.11 V.A.10 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by GSK Amgen at the request of OIG, whichever is later, OIG will notify GSK Amgen if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, GSK Amgen may continue to engage the IRO.

IRO Engagement. GSK Par shall engage an IRO (or IRO(s)) that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph D. D, below. Within 30 days after OIG receives the information identified in Section V.A.11 V.A.9 of the CIA or any additional information submitted by GSK Par in response to a request by OIG, whichever is later, OIG will notify GSK Par if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, GSK Par may continue to engage the IRO. If GSK Par engages a new IRO during the term of the CIA, this IRO shall also meet the requirements of this Appendix. If a new IRO is engaged, GSK Par shall submit the information identified in Section V.A.11 V.A.9 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by GSK Par at the request of OIG, whichever is later, OIG will notify GSK Par if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, GSK Par may continue to engage the IRO.